$VERU

For those chasing $VERU at >$1B valuation, be careful: 1) MoA (tubulin inhibitor) is not validated for #COVID19 or ARDS 2) Very small sample size: N~150 vs. other COVID19 pivotal trials (most N>1,000) 3) CEO has a long history of touting questionable data